Anthony Oliva

Dr. Anthony Oliva

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in Nature Medicine
Verified
Journal Article
Open access
PDF file
BRBrian G. Rash
Brian G. Rash
KRKevin N. Ramdas
Kevin N. Ramdas
NANataliya Agafonova
Nataliya Agafonova
ENEric Naioti
Eric Naioti
LMLisa McClain-Moss
Lisa McClain-Moss
JHJoshua M. Hare
Joshua M. Hare
Alzheimer’s disease (AD) is characterized by progressive cognitive decline, severe brain atrophy and neuroinflammation. We conducted a randomized, double-blind, placebo-controlled, parallel-group phase 2a clinical trial that tested the safety and efficacy of laromestrocel, a bone-marrow-derived, allogeneic mesenchymal stem-cell therapy, in slowing AD clinical progression, atrophy and neuroinflammation. Participants across ten centers in the United States were randomly assigned 1:1:1:1 to four infusion groups: group 1 (placebo; four monthly infusions, n = 12); group 2 (25 million cells, one infusion followed by three monthly infusions of placebo, n = 13); group 3 (25 million cells; four monthly doses, n = 13); and group 4 (100 million cells; four monthly doses, n = 11). The study met its primary end point of safety; the rate of treatment-emergent serious adverse events within 4 weeks of any infusion was similar in all four groups: group 1, 0% (95% CI 0–26.5%); group 2, 7.7% (95% CI 0.2–36%); group 3, 7.7% (95% CI 0.2–36%) and group 4, 9.1% (95% CI 0.2–41.3%). Additionally, there were no reported infusion-related reactions, hypersensitivities or amyloid-related imaging abnormalities. Laromestrocel improved clinical assessments at 39 weeks compared to placebo, as measured by a composite AD score (secondary end point was met: group 2 versus placebo change: 0.38; 95% CI −0.06–0.82), Montreal cognitive assessment and the Alzheimer’s Disease Cooperative Study Activities of Daily Living. At 39 weeks, Laromestrocel slowed the decline of whole brain volume compared to placebo (n = 10) by 48.4% for all treatment groups combined (groups 2–4: P = 0.005; n = 32) and left hippocampal volume by 61.9% (groups 2–4, P = 0.021; n = 32), and reduced neuroinflammation as measured by diffusion tensor imaging. The change in bilateral hippocampal atrophy correlated with the change in mini-mental state exam scores (R = 0.41, P = 0.0075) in all study patients (N = 42). Collectively these results support safety of single and multiple doses of laromestrocel treatment for mild AD and provide indications of efficacy in combating decline of brain volume and potentially cognitive function. Larger-scale clinical trials of laromestrocel in AD are warranted. ClinicalTrials.gov registration: NCT05233774.

31 March 2022 in Alzheimer's & Dementia
Verified
Journal Article
Open access
MBMark Brody
Mark Brody
MAMarc Agronin
Marc Agronin
BHBrad J. Herskowitz
Brad J. Herskowitz
SBSusan Y. Bookheimer
Susan Y. Bookheimer
GSGary W. Small
Gary W. Small
BBBernard Baumel
Bernard Baumel
Hypothesis: We hypothesized that Lomecel‐B, an allogeneic medicinal signaling cell (MSC) therapeutic candidate for Alzheimer's disease (AD), is safe and potentially disease‐modifying via pleiotropic mechanisms of action.Key Predictions: We prospectively tested the predictions that Lomecel‐B administration to mild AD patients is safe (primary endpoint) and would provide multiple exploratory indications of potential efficacy in clinical and biomarker domains (prespecified secondary/exploratory endpoints).Strategy and Key Results: Mild AD patient received a single infusion of low‐ or high‐dose Lomecel‐B, or placebo, in a double‐blind, randomized, phase I trial. The primary safety endpoint was met. Fluid‐based and imaging biomarkers indicated significant improvement in the Lomecel‐B arms versus placebo. The low‐dose Lomecel‐B arm showed significant improvements versus placebo on neurocognitive and other assessments.Interpretation: Our results support the safety of Lomecel‐B for AD, suggest clinical potential, and provide mechanistic insights. This early‐stage study provides important exploratory information for larger efficacy‐powered clinical trials.

1 April 2022 in The Journal of Frailty & Aging
Verified
Journal Article
Open access
PDF file
Matteo  CesariMatteo Cesari
Matteo Cesari
RBRoberto Bernabei
Roberto Bernabei
BVB. Vellas
B. Vellas
RFRoger Fielding
Roger Fielding
DRDaniel Rooks
Daniel Rooks
YRY. Rolland
Y. Rolland
Sarcopenia and frailty represent two burdensome conditions, contributing to a broad spectrum of adverse outcomes. The International Conference on Frailty a

28 September 2001 in Journal of Comparative Neurology
Verified
Journal Article
Closed access
PDF file
MJMinghui Jiang
Minghui Jiang
AOAnthony Oliva
Anthony Oliva
TLTrang Lam
Trang Lam
JSJohn W. Swann
John W. Swann

17 September 2019 in Aging Medicine
Verified
Journal Article
Open access
PDF file
AOAnthony Oliva
Anthony Oliva
LMLisa McClain‐Moss
Lisa McClain‐Moss
APAndrea Pena
Andrea Pena
ADAmy Drouillard
Amy Drouillard
JHJoshua M. Hare
Joshua M. Hare
Extraordinary advances in medicine and public health have contributed to increasing life expectancy worldwide. However, health span—“healthy aging”—has paradoxically lagged to parallel this increase. Consequently, aging‐associated illnesses, such as Alzheimer's disease and aging frailty, are having a growing impact on patients, their families, and entire health‐care systems. Typically, such disorders have been treated as isolated disease entities. However, the inextricable links between aging‐associated disorders and the aging process itself have become increasingly recognized, leading to formation of the field of geroscience. The geroscience concept is that treating the aging process itself should lead to treatment and prevention of aging‐related disorders. However, the aging process is complex, dictated by highly interrelated pleiotropic processes. As such, therapeutics with pleiotropic mechanisms of action (either alone, or as part of combinatorial strategies) will be required for preventing and treating both aging and related disorders. Mesenchymal stem cells (MSCs) have multiple mechanisms of action that make these highly promising geroscience therapeutic candidates. These cells have a high safety profile for clinical use, are amenable to allogeneic use since tissue‐type matching is not required, and can have sustained activity after transplantation. Herein, we review preclinical and clinical data supporting the utility of allogeneic MSCs as a geroscience therapeutic candidate.

1 April 2022 in The Journal of Frailty & Aging
Verified
Journal Article
Open access
KYK. Yousefi
K. Yousefi
KRK.N. Ramdas
K.N. Ramdas
JRJ.G. Ruiz
J.G. Ruiz
JWJ. Walston
J. Walston
HAH. Arai
H. Arai
AOAnthony Oliva
Anthony Oliva
Frailty in older adults is a rapidly growing unmet medical need. It is an aging-related syndrome characterized by physical decline leading to higher risk of adverse health outcomes. To evaluate the efficacy of Lomecel-B, an allogeneic medicinal signaling cell (MSC) formulation, in older adults with frailty. This multicenter, randomized, parallel-arm, double-blinded, and placebo-controlled phase 2b trial is designed to evaluate dose-range effects of Lomecel-B for frailty on physical functioning, patient-reported outcomes (PROs), frailty status, and biomarkers. Eight enrolling clinical research centers, including the Miami Veterans Affairs Medical Center. Target enrollment is 150 subjects aged 70-85 years of any race, ethnicity, or gender. Enrollment criteria include a Clinical Frailty Score of 5 ("mild") or 6 ("moderate"), a 6MWT of 200-400 m, and serum tumor necrosis factor-alpha (TNF-α) ≥2.5 pg/mL. A single intravenous infusion of Lomecel-B (25, 50, 100, or 200 million cells) or placebo (N=30/arm). Patients are followed for 365 days for safety, and the efficacy assessments performed at 90, 180, and 270 days. The primary endpoint is change in 6MWT in the Lomecel-B-treated arms versus placebo at 180 days post-infusion. Secondary and exploratory endpoints include change in: 6MWT and other physical function measures at all time points; PROs; frailty status; cognitive status; and an inflammatory biomarkers panel. A pre-specified sub-study examines vascular/endothelial biomarkers. Safety is evaluated throughout the trial. The trial is conducted under a Food and Drug Administration Investigational New Drug (IND), with Institutional Review Board approval, and monitoring by an NIH-appointed independent Data Safety Monitoring Board. This clinical trial investigates the use of a regenerative medicine strategy for frailty in older adults. The results will further the understanding of the potential for Lomecel-B in the geriatric condition of frailty.